GVR Report cover Hemorrhagic Stroke Treatment Devices Market (2026 - 2033)Report

Hemorrhagic Stroke Treatment Devices Market (2026 - 2033)

Size, Share & Trends Analysis Report By Treatment Type (Aneurysm & Hemorrhagic Stroke Interventions, Adjunctive & Vasospasm Management Devices), By End-use (Hospitals, Ambulatory Surgery Centers), By Region, And Segment Forecasts

Market Size, 2025

$1.9B

Market Estimate, 2026

$2.0B

Market Forecast, 2033

$3.1B

CAGR, 2026–2033

6.2%

Hemorrhagic Stroke Treatment Devices Market Summary

The global hemorrhagic stroke treatment devices market size was valued at USD 1.9 billion in 2025 and is projected to grow from USD 2.0 billion in 2026 to USD 3.1 billion by 2033, at a CAGR of 6.2% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 43.8% in 2025. The industry is driven by the rising incidence of intracerebral hemorrhage and cerebral aneurysms, particularly among aging populations and patients with hypertension.

Hemorrhagic stroke treatment devices market overview: Grand View Research estimates the global market size at USD 1.9 billion in 2025, projected to grow from USD 2.0 billion in 2026 to USD 3.1 billion by 2033 at a 6.2% CAGR, with regional growth momentum.Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, icon Download Free Sample Report

Key Market Trends & Insights

  • By treatment type: Aneurysm & hemorrhagic stroke interventions dominated the market in 2025.
  • By end-use: Hospitals segment led the market with the largest revenue share in 2025.

Regional Highlights

  • Largest regional market: North America (43.8% revenue share, 2025)
  • Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
  • By country: The U.S. held the largest market share in 2025.

Market Size & Forecast

  • Market size in 2025: USD 1.9 Billion
  • Estimated market size in 2026: USD 2.0 Billion
  • Projected market size by 2033: USD 3.1 Billion
  • CAGR (2026-2033): 6.2%
Ask a question about the hemorrhagic stroke treatment devices market
Try asking
✓Every figure cited from GVR research Prefer the report? Download free sample →


The rising incidence of intracerebral hemorrhage and cerebral aneurysms increases the number of patients requiring urgent medical intervention, directly boosting demand for hemorrhagic stroke treatment devices. As more cases are diagnosed, healthcare providers adopt advanced endovascular and minimally invasive technologies to improve outcomes, which in turn drives market growth and encourages continued innovation and investment in treatment solutions.

Hemorrhagic stroke treatment devices market size and growth forecast (2023-2033)

To learn more about this report, icon Download Free Sample Report

Multiple countries across Europe continue to report a significant hemorrhagic stroke burden, contributing to anticipated market expansion.

Forecasted number of new intracerebral hemorrhage cases across selected European countries, 2050

To learn more about this report, icon Download Free Sample Report

Global incidence, prevalence, and mortality of intracerebral hemorrhage as per the WSO 2025 factsheet

To learn more about this report, icon Download Free Sample Report

According to the Global Stroke Fact Sheet 2025 published by the World Stroke Organization, more than 12 million new stroke cases occur annually, and nearly one in four people worldwide will experience a stroke during their lifetime. The report indicates that intracerebral hemorrhage (ICH) accounts for 28.8% and subarachnoid hemorrhage (SAH) for 5.8% of all incident strokes, underscoring the substantial hemorrhagic stroke burden. The growing prevalence of this disease is expected to be a key driver of market growth during the forecast period.

Global incidence, prevalence, and mortality of subarachnoid hemorrhage as per WSO 2025 factsheet

To learn more about this report, icon Download Free Sample Report

According to data published by the American Heart Association in February 2022, hemorrhagic strokes account for approximately 10% of the nearly 800,000 stroke cases reported annually in the U.S., and they are associated with a higher mortality rate compared to other stroke types. This considerable disease burden is anticipated to drive demand for hemorrhagic stroke treatment devices.

Hemorrhagic stroke and hypertension-related age-adjusted mortality rates per 100,000, by states in the U.S., 2021 to 2023

To learn more about this report, icon Download Free Sample Report

The increasing focus on minimally invasive treatment strategies, including early minimally invasive evacuation of intracerebral hemorrhage (ICH) and endoscopic hematoma removal, is expected to be a key driver of market growth over the forecast period. Ongoing clinical trials are supporting the development of technologies that improve procedural safety and clinical outcomes. For example, in April 2024, NICO Corporation reported positive results from the ENRICH (Early MiNimally-invasive Removal of ICH) clinical trial, showing that early minimally invasive parafascicular surgery (MIPS) using its BrainPath and Myriad systems was safe and demonstrated superior outcomes compared with guideline-based medical management alone, the current standard of care for ICH.

ENRICH Trials Results

Primary Endpoints

Endpoint

MIPS

Medical

Management (MM)

Treatment Effect

Utility-weighted modified Rankin Scale (mRS) (180 days)

0.458

0.374

Difference with 98.1% posterior probability of superiority (95% CI: 0.005-0.163)

Mortality (30 days)

9.30%

18.10%

Reduced mortality with MIPS

ICU Length of Stay

-

-

-2.8 days with MIPS

Hospital Length of Stay

-

-

-3.1 days with MIPS

Get access to detailed company insights of key market participants. To know more request a free sample copy

Source: NICO Corporation, Grand View Research Analysis

Secondary Endpoints

Endpoint

MIPS

MM

Outcome

mRS (7, 30, 90, 120, 180 days)

Favorable

Reference

Ordinal logistic regression favored MIPS at all time points

Change in hemorrhage volume

-44 mL

+4 mL

Significant reduction with MIPS

End-of-treatment volume <15 mL

73% achieved

-

Majority achieved target with MIPS

Source: NICO Corporation, Grand View Research Analysis

“The results of the ENRICH trial not only demonstrate the efficacy and safety of MIPS, but they also herald a transformative milestone for the entire stroke community, changing the ICH treatment paradigm through a standardized approach and advanced technology,” said Gustavo Pradilla, MD, co-lead investigator for ENRICH, associate professor of neurosurgery at Emory University School of Medicine, and chief of neurosurgery for Grady Memorial Hospital.

The growing number of clinical trials led by research institutions, academic centers, and industry players is a major driver of the hemorrhagic stroke treatment devices market. These studies strengthen clinical evidence, support regulatory approvals, and build physician confidence in minimally invasive and next-generation technologies. In addition, they promote innovation, broaden treatment applications, and accelerate the adoption and commercialization of advanced devices, thereby fueling sustained market growth.

Some of the notable clinical trials focusing on hemorrhagic stroke treatment devices are highlighted as follows:

Study Title

Conditions

Interventions

Sponsor

Enrollment

Primary Completion Date

Evaluating Functional Outcomes of 3D-Printed Splints in Post-Stroke Upper Limb Recovery

Stroke|Stroke Rehabilitation|Hemiparesis of the Upper Limb Following Stroke

DEVICE: 3D Printed splint|DEVICE: conventional splint

King Saud University

100

9/30/2027

Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve

Hydrocephalus|Hydrocephalus in Children|NPH (Normal Pressure Hydrocephalus)|IIH - Idiopathic Intracranial Hypertension|Brain Tumor|Post-Traumatic Hydrocephalus|Hemorrhagic Stroke

DEVICE: CODMAN CERTAS Plus Programmable Valve

Integra LifeSciences Corporation

158

8/31/2027

Source: ClinicalTrials.gov

The advancements in neurointerventional technologies are driving the hemorrhagic stroke treatment devices market by enabling safer, faster, and more effective minimally invasive procedures. Innovations in embolization systems, flow diverters, stents, and image-guided catheters improve outcomes, reduce risks and recovery time, and support broader adoption across comprehensive stroke centers.

In September 2025, Siemens Healthineers and Stryker announced a strategic partnership focused on advancing neurovascular robotics. The collaboration aims to develop an integrated robotic system capable of supporting a wide range of elective and emergency neurovascular procedures, including stroke and aneurysm treatments. By combining Siemens Healthineers’ expertise in robotics and image-guided therapy with Stryker’s neurovascular technologies, the partnership will address robotic system design, device and implant integration, imaging-enabled navigation, and workflow optimization.

“Neurovascular diseases - primarily strokes and aneurysms - carry a massive global burden. Stroke is the second-leading cause of death and the third-leading cause of disability in adults globally,” said Carsten Bertram, head of Advanced Therapies at Siemens Healthineers. “We are excited to announce this partnership, especially with Stryker, a leading player in the field of neurovascular care. Together, we are uniquely positioned to create an ecosystem of image-guidance, robotics, and devices. This meaningful innovation will enable physicians to deliver more precise and timely care to patients around the world.” 

“Stryker and Siemens Healthineers have the joint goal to advance neurovascular care through innovation,” said Jim Marucci, president of Stryker’s Neurovascular division. “By combining our deep expertise in stroke therapy devices with the leadership of Siemens Healthineers in robotics and imaging, we aim to simplify workflows, enhance precision, and accelerate care. Together, we are taking an important step toward transforming how neurovascular procedures are performed - and ultimately, working to improve outcomes for patients worldwide.”

Market Dynamics

The hemorrhagic stroke treatment devices market is driven by the growing demand for timely, targeted management of intracerebral and intraventricular hemorrhage, including hematoma evacuation, intracranial pressure control, and ventricular drainage. The shift toward minimally invasive treatment is supporting the adoption of catheter-based, stereotactic, endoscopic, aspiration, and image-guided devices that enable targeted intervention with reduced tissue disruption. Technological advancements are further improving procedural precision, clot removal, and access to challenging anatomical locations, while the availability of specialized neurosurgical expertise, procedural complexity, high treatment costs, and differences in hospital infrastructure continue to influence device adoption.

The growing adoption of minimally invasive hematoma evacuation techniques is driving demand for hemorrhagic stroke treatment devices as healthcare providers seek treatment approaches that reduce surgical trauma while enabling effective clot removal. Stereotactic aspiration, endoscopic evacuation, catheter-based approaches, and image-guided techniques support targeted access to intracerebral hematomas and can reduce disruption of surrounding healthy brain tissue. Recent clinical evidence has further strengthened interest in minimally invasive approaches for appropriately selected patients, supporting continued development and adoption of specialized evacuation devices.

The hemorrhagic stroke treatment devices market is restrained by the complexity of neurosurgical and neurointerventional procedures, which require specialized clinical expertise, advanced imaging systems, and dedicated stroke-care infrastructure. Limited availability of trained neurosurgeons and neurointerventional specialists, particularly in developing healthcare systems, restricts the use of advanced treatment devices. High acquisition and procedure-related costs also create challenges for hospitals with limited healthcare budgets. In addition, variations in treatment protocols and patient suitability can affect the adoption of specialized devices.

The development of advanced minimally invasive technologies presents a strong opportunity for market expansion. Manufacturers are focusing on devices that improve catheter navigation, evacuation, procedural precision, and access to difficult intracranial locations. Innovations incorporating improved visualization, image guidance, aspiration mechanisms, and compact device designs can support more efficient treatment while reducing surgical trauma. Expansion of specialized stroke centers and greater clinical acceptance of minimally invasive approaches can further create opportunities for advanced hemorrhagic stroke treatment devices.

 

Market Concentration & Characteristics

The industry demonstrates a high degree of innovation, driven by continuous advancements in minimally invasive and endovascular technologies. Manufacturers are focusing on improved device precision, better navigation in complex cerebral vasculature, and enhanced safety profiles to reduce procedural risks. Ongoing R&D, clinical trials, and integration of imaging-guided solutions are accelerating the introduction of next-generation devices and expanding treatment options. For instance, in June 2025, Viz.ai announced that it received U.S. FDA 510(k) clearance for Viz Subdural Plus, the first comprehensive solution for quantifying subdural hemorrhage collections on non-contrast CT scans. The module automatically labels subdural collections and reports key measurements, such as volume, thickness, and midline shift, to support faster and more informed clinical decision-making.

“Viz Subdural Plus introduces a new level of precision in diagnosing and monitoring subdural hemorrhage,” said David J. Altschul, MD, Division Chief Cerebrovascular Neurosurgery at Montefiore Health System. “Having automated volume and max thickness measurements at our fingertips allows us to make faster, more informed treatment decisions-especially critical in managing elderly patients or those on anticoagulants. As we increasingly turn to minimally invasive options like MMA embolization to reduce recurrence, tools like Viz Subdural Plus are essential to guiding timely and effective treatment.”

The industry is experiencing a moderate-to-high level of merger and acquisition activity, driven by companies seeking to expand their neurovascular portfolios and enhance their technological capabilities. Larger medical device firms are acquiring specialized innovators to gain access to advanced endovascular and aneurysm treatment technologies. These strategic deals are also helping companies expand their global reach, accelerate regulatory approvals, and enhance their competitive positioning in a rapidly evolving market. For instance, in February 2025, Stryker completed its acquisition of Inari Medical, Inc., a specialist in non-thrombolytic solutions for the removal of venous thromboembolism (VTE) clots. The deal strengthens Stryker’s peripheral vascular portfolio and expands its footprint in the rapidly growing VTE treatment market.

Hemorrhagic Stroke Treatment Devices Industry Dynamics

To learn more about this report, icon Download Free Sample Report

“The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio,” said Kevin Lobo, Chair and Chief Executive Officer, Stryker. “We look forward to welcoming the talented Inari team to Stryker and working together to improve outcomes for patients worldwide.”

Regulations play a critical role in shaping the industry by ensuring high standards of safety, clinical effectiveness, and post-market surveillance. Stringent approval pathways and clinical evidence requirements can lengthen time-to-market and increase development costs for manufacturers. However, clear regulatory frameworks also build physician and patient confidence, support wider adoption of innovative devices, and promote long-term market stability.

Hemorrhagic stroke treatment devices are classified as medical devices based on their risk and intended use, primarily falling under Class II (moderate risk) and Class III (high risk) categories. Class II devices typically require 510(k) clearance, whereas high-risk implantable devices, such as aneurysm implants and flow diverters, require Premarket Approval (PMA) to ensure safety and effectiveness.

The end user concentration in the industry is high, with demand largely centered on tertiary hospitals and comprehensive stroke centers that manage complex neurovascular emergencies. These facilities account for most of the device utilization due to their access to advanced imaging, neurosurgical expertise, and 24/7 intervention capabilities. While ambulatory and specialty centers are emerging, hospitals continue to represent the most concentrated and influential end-user group in the market.

Analyst Perspective

The hemorrhagic stroke treatment devices market is highly competitive, with established and emerging players competing through technological innovation, clinical performance, product breadth, and physician adoption. Leading companies such as Medtronic, Stryker, Terumo Corporation, Penumbra, Boston Scientific, and Johnson & Johnson leverage broad neurovascular portfolios, established clinical expertise, regulatory capabilities, and extensive distribution networks. Specialized players such as Balt, phenox, Acandis, and Scientia Vascular differentiate themselves through targeted solutions for aneurysm embolization, flow diversion, intrasaccular treatment, and other minimally invasive interventions. The need for improved device navigability, deployment precision, procedural safety, and compatibility with complex cerebrovascular anatomies also shapes competition.

Treatment Type Insights

Aneurysm & hemorrhagic stroke interventions dominated the market in 2025 and are also expected to be the fastest-growing segment during the forecast period. This is driven by the high clinical urgency of aneurysm-related hemorrhages and the increasing preference for minimally invasive endovascular procedures such as coiling, flow diversion, and embolization. Continuous technological advancements, improvements in clinical outcomes, and the expanding availability of specialized neurointerventional centers are further accelerating growth in this segment.

Adjunctive & vasospasm management devices are witnessing significant growth in the hemorrhagic stroke treatment devices market due to their increasing use in managing complications associated with intracranial hemorrhage, particularly cerebral vasospasm following subarachnoid hemorrhage. These devices support restoration of cerebral blood flow, vessel stabilization, and prevention of secondary ischemic injury in high-risk patients. Advancements in balloon angioplasty catheters, intra-arterial delivery systems, and vasospasm management technologies, along with growing clinician expertise, are supporting wider adoption across specialized neurovascular and stroke centers.

End-use Insights

Hospitals segment led the market with the largest revenue share in 2025, as they remain the primary centers for emergency stroke management, advanced neuroimaging, and complex surgical and endovascular interventions. The concentration of specialized stroke units, neurosurgeons, and neurointerventional radiologists within hospitals enables rapid diagnosis and timely treatment, which is critical for hemorrhagic stroke outcomes. In addition, higher capital investment capacity, favorable reimbursement for inpatient procedures, and access to advanced infrastructure have reinforced hospitals’ leading share compared to other care settings.

Hemorrhagic Stroke Treatment Devices Market Share

To learn more about this report, icon Download Free Sample Report

Ambulatory Surgical Centers (ASCs) are expected to be the fastest-growing end-use segment in the market during the forecast period, driven by the shift toward minimally invasive and image-guided procedures. Advances in endovascular technologies are enabling select stroke interventions to be performed safely in high-acuity outpatient settings, reducing hospital stays and overall treatment costs. Growing patient preference for faster recovery, coupled with expanding reimbursement support and investment in specialized ASC infrastructure, is further accelerating adoption across developed healthcare markets.

Regional Insights 

North America hemorrhagic stroke treatment devices market held the largest share and accounted for 43.8% of global revenue in 2025, evolving through increased use of minimally invasive and image-guided interventions in advanced stroke care centers. Strong reimbursement support, well-established healthcare infrastructure, and broad clinical acceptance are driving adoption. Continuous product innovation and a growing emphasis on rapid, outcome-focused treatment further support market growth across the region.

Hemorrhagic Stroke Treatment Devices Market Trends, by Region, 2026 - 2033

To learn more about this report, icon Download Free Sample Report

U.S. Hemorrhagic Stroke Treatment Devices Market Trends

The hemorrhagic stroke treatment devices market in the U.S. is progressing with the growing use of advanced endovascular and minimally invasive procedures in specialized stroke centers. Favorable reimbursement structures, strong clinical adoption, and continuous technological innovation are supporting market expansion. A strengthened focus on rapid intervention and outcome improvement is further accelerating the demand for next-generation treatment devices.

Incidence of Strokes in the U.S. (2021)

To learn more about this report, icon Download Free Sample Report

Europe Hemorrhagic Stroke Treatment Devices Market Trends

The hemorrhagic stroke treatment devices market in Europe is driven by increasing adoption of minimally invasive and endovascular solutions across leading healthcare systems. A strong emphasis on early diagnosis, comprehensive stroke care pathways, and supportive reimbursement frameworks is boosting demand for advanced treatment technologies. In addition, collaborative clinical research and growing investments in neurointerventional infrastructure are accelerating the uptake of this technology across both Western and emerging European markets.

The UK hemorrhagic stroke treatment devices market is evolving with the greater use of minimally invasive, image-guided interventions across specialized stroke centers. Continued NHS investment in stroke pathways and faster diagnosis is supporting wider adoption of advanced neurointerventional devices. In addition, strong clinical guidelines and research-driven innovation are helping integrate newer technologies into routine stroke care.

Stroke Incidence in the UK with Focus on Young Patients (2025)

Indicator

Value

Total annual stroke cases in the UK

>100,000 cases per year

Estimated annual strokes in young people

~10,000 cases

Proportion of young strokes

~10% of total strokes

Trend in young stroke incidence

Increasing

Source: The United Kingdom Young Stroke Study (UKYSS)

The hemorrhagic stroke treatment devices market in France is characterized by a strong emphasis on advanced neurointerventional care and the widespread adoption of minimally invasive technologies. Well-established healthcare infrastructure and supportive reimbursement policies are encouraging the use of advanced treatment devices in major stroke centers. In addition, ongoing clinical research and collaboration between hospitals and device manufacturers are fostering faster integration of innovative solutions into standard care pathways.

Stroke Hospitalization and Treatment Utilization in France (2022)

Indicator

Hemorrhagic Stroke

Adults hospitalized due to stroke (2022)

122,422 (total strokes)

Estimated total stroke cases

1,086,795 (total strokes)

Admission to stroke intensive care unit

46.8% (overall)

Admission to rehabilitation unit (within 6 months)

41.70%

Neurologist consultation (within 6 months)

18.80%

Cardiologist consultation (within 6 months)

10.90%

Mortality rate at 1 year

37.90%

Source: Science Direct

Asia Pacific Hemorrhagic Stroke Treatment Devices Market Trends

The hemorrhagic stroke treatment devices market in Asia Pacific is expanding rapidly, driven by rapid healthcare advancements and increasing investments in neurointerventional care are fueling strong demand for innovative and minimally invasive technologies. Countries like Japan, South Korea, and Australia are driving early adoption, while emerging markets such as India and Southeast Asia are expanding access through improved infrastructure and training. In addition, increasing stroke awareness and improved reimbursement frameworks are facilitating the broader adoption of advanced treatment devices across the region.

The China hemorrhagic stroke treatment devices market is witnessing significant growth, due to the rising use of minimally invasive and endovascular treatment approaches. Strong government investment in stroke centers, improvements in regulatory pathways, and increased adoption of domestically manufactured devices are key trends. Growing reimbursement coverage and enhanced physician training are further supporting wider penetration of advanced treatment technologies across urban and regional healthcare facilities.

Stroke Incidence in China by Gender (2021)

To learn more about this report, icon Download Free Sample Report

Latin America Hemorrhagic Stroke Treatment Devices Market Trends

The hemorrhagic stroke treatment devices market in Latin America is experiencing significant growth, driven by rising healthcare expenditure and expanding access to advanced neurointerventional procedures, which are driving demand for innovative devices. Governments and private providers are investing in stroke care infrastructure, while growing awareness and screening programs are improving early diagnosis and treatment rates. Despite economic variability across countries, the trend toward the adoption of minimally invasive technologies and partnerships with global device manufacturers is strengthening market growth.

MEA Hemorrhagic Stroke Treatment Devices Market Trends

The hemorrhagic stroke treatment devices market in the Middle East & Africa is evolving significantly as growing healthcare investments and expanding neurointerventional capabilities are driving higher adoption of advanced treatment technologies. Rising awareness of stroke care, an increasing number of trained specialists, and government initiatives to improve emergency response infrastructure are key trends shaping demand across the region.

Stroke Rehabilitation Care Pathway in Saudi Arabia

To learn more about this report, icon Download Free Sample Report

Key Hemorrhagic Stroke Treatment Devices Company Insights

Key players operating in the hemorrhagic stroke treatment devices market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.

Key Hemorrhagic Stroke Treatment Devices Companies

The following key companies have been profiled for this study on the hemorrhagic stroke treatment devices market.

  • Medtronic

  • Terumo Corporation

  • Balt

  • Scientia Vascular, Inc.

  • MicroPort Scientific Corporation

  • Johnson & Johnson (MedTech)

  • phenox GmbH (Wallaby Medical)

  • Acandis GmbH

  • B. Braun SE

  • Integra LifeSciences

  • Infinity Neuro LLC

  • Penumbra, Inc.

  • Boston Scientific Corporation

  • Stryker

  • Peter LAZIC GmbH

Competitive Benchmarking

Category

Operating Strategies

Competitive Edge

Weakness

Established Players (Medtronic, Terumo Corporation, Balt, MicroPort Scientific Corporation, Johnson & Johnson (MedTech), B. Braun SE, Integra LifeSciences, Penumbra, Inc., Boston Scientific Corporation, Stryker)

  • Established players focus on expanding neurovascular portfolios through advanced coils, flow diverters, embolization systems, and delivery technologies.
  • Companies strengthen market presence through product launches, clinical evidence, regulatory approvals, strategic partnerships, and expansion across specialized stroke centers.
  • Broad product portfolios, established clinical evidence, strong physician relationships, and extensive distribution networks provide advantages across complex neurovascular procedures.
  • Strong research capabilities and regulatory expertise enable established players to commercialize technologically advanced devices and address diverse aneurysm anatomies.
  • Large organizational structures and complex regulatory processes can slow product development, commercialization, and responses.
  • Premium pricing of advanced neurovascular devices can limit adoption among cost-sensitive hospitals and healthcare systems in emerging markets.

Emerging Players (Scientia Vascular, Inc., phenox GmbH (Wallaby Medical), Acandis GmbH, Infinity Neuro LLC, Peter LAZIC GmbH)

  • Emerging players focus on specialized neurovascular technologies targeting complex aneurysms, vasospasm, embolization, and minimally invasive hemorrhagic stroke procedures.
  • Companies pursue regulatory clearances, clinical studies, strategic collaborations, and regional commercialization to establish credibility and expand physician adoption.
  • Focused product portfolios enable emerging companies to address specific clinical needs with specialized designs and differentiated treatment approaches.
  • Greater organizational flexibility supports faster innovation, customized physician engagement, and rapid adaptation to evolving neurovascular treatment requirements.
  • Limited clinical evidence, physician familiarity, and long-term outcome data can constrain adoption compared with established neurovascular device manufacturers.
  • Smaller sales networks and restricted financial resources can limit regulatory expansion, manufacturing scale, market access, and international commercialization.

Recent Developments

  • In December 2025, Penumbra Inc. received CE Mark approval for its MIDWAY and ACCESS25 delivery catheters. These catheters are now commercially available across Europe, further strengthening Penumbra’s neuro access platform.

  • In October 2025, Penumbra launched the SwiftSET Coil, an advanced complex embolization coil designed for adaptive vessel occlusion. The device features a unique shape configuration that improves vessel wall apposition, allowing smooth deployment and natural conformity within tight anatomical spaces. This design enables dense and controlled occlusion, particularly in small and challenging vessels.

  • In July 2025, Stryker announced the commercial launch of the Surpass Elite Flow Diverter across the U.S., South Korea, and Europe. This next-generation device represents a significant advancement in flow diversion therapy, combining an enhanced implant design with a proprietary surface modification to improve clinical performance and reduce thrombin generation.

  • In July 2025, Boston Scientific Corporation announced the launch of its Neuroform EZ Stent System in the U.S. and Europe. This fourth-generation intracranial aneurysm stent is designed for use with endovascular coiling the treat wide-necked aneurysms, and commercial rollout has been initiated immediately across both regions.

Hemorrhagic Stroke Treatment Devices Market Report Scope

Report Attribute

Details

Market size in 2025

USD 1.9 billion

Estimated market size in 2026

USD 2.0 billion

Projected market size by 2033

USD 3.1 billion

Growth rate

CAGR of 6.2% from 2026 to 2033

Base year for estimation

2025

Historical data

2021 - 2024

Forecast period

2026 - 2033

Quantitative units

Revenue in USD million/billion and CAGR from 2026 to 2033

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Treatment type, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Mexico; Germany; UK; France; Norway; Italy; Denmark; Sweden; Spain; China; Japan; India; South Korea; Thailand; Australia; Brazil; Argentina; Saudi Arabia; UAE; South Africa; Kuwait

Key companies profiled

Medtronic; MicroVention, Inc. (Terumo Corporation); Balt; Scientia Vascular, Inc.; MicroPort Scientific Corporation; Johnson & Johnson (MedTech); phenox GmbH (Wallaby Medical); Acandis GmbH; B. Braun SE; Integra LifeSciences; Infinity Neuro LLC; Penumbra, Inc.; Boston Scientific Corporation; Stryker; Peter LAZIC GmbH

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Global Hemorrhagic Stroke Treatment Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hemorrhagic stroke treatment devices market report on the basis of treatment type, end-use, and region:

Global Hemorrhagic Stroke Treatment Devices Market Report Segmentation

To learn more about this report, icon Download Free Sample Report

  • Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)

    • Aneurysm & Hemorrhagic Stroke Interventions

      • By Indication

        • Intracranial Aneurysm

        • cSDH (MMA Embolization)

        • AVM & AVF Embolization

      • By Device

        • Embolization Coiling Systems

          • Bare Platinum Coils

          • Coated / Bioactive Coils

        • Flow Diversion Systems

          • Standard Flow-Diverting Stents (e.g., Pipeline)

          • Next-Generation / Surface-Modified Flow Diverters

        • Intrasaccular Flow Disruption Devices

          • Woven EndoBridge (WEB)

          • Contour Neurovascular System

          • Luna Aneurysm Embolization System

        • Liquid Embolization Agents

          • Non-Adhesive Liquid Embolics (Onyx, Squid, PHIL)

          • Adhesive Liquid Embolics (NBCA)

    • Adjunctive & Vasospasm Management Devices

      • Vasospasm Balloon Angioplasty Systems

      • Coil-Assisted Adjunctive Devices (Balloon-assisted and stent-assisted)

    • Ancillary & Procedural Access Devices

      • Guiding & Distal Access Catheters

      • Microcatheters

      • Access Sheaths & Wires

  • End Use Outlook (Revenue, USD Million, 2021 - 2033)

    • Hospitals

    • Specialty Neurosurgery Centers

    • Ambulatory Surgical Centers

  • Regional Outlook (Revenue, USD Million, 2021 - 2033)

    • North America

      • U.S.

      • Canada

      • Mexico

    • Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Sweden

      • Denmark

      • Norway

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

      • Thailand

    • Latin America

      • Brazil

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

Research Methodology

The hemorrhagic stroke treatment devices market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each hemorrhagic stroke treatment devices segment quantified using the revenue-capture definitions in the table below.

Segment Definition 

Segment - Treatment type

Revenue capture definition

Aneurysm & Hemorrhagic Stroke Interventions

Sales value generated from definitive therapeutic implants and permanent occlusion agents. It measures direct manufacturer-level revenue from primary treatment tools, including detachable embolization coils, flow diversion stents, intrasaccular disruption devices, and liquid embolic systems used to seal, divert flow, or obliterate cerebral aneurysms and vascular malformations.

Adjunctive & Vasospasm Management Devices

 

Revenue earned by medical device manufacturers for supportive endovascular instruments used alongside primary implants or for treating secondary vascular complications. This encompasses remodeling balloon catheters, neck-bridging temporary stents, intracranial angioplasty balloon systems, and intra-arterial vasospasm dilation tools designed to stabilize coils or reopen vasospastic cerebral arteries.

Ancillary & Procedural Access Devices

Financial proceeds accrued from foundational endovascular delivery systems and navigational consumables. It accounts for manufacturers' revenues from microcatheters, steerable guidewires, guiding catheters, long-sheath systems, and distal-access catheters required to establish, maintain, and navigate a secure vascular pathway to the target lesion.

Estimation Model

Market Estimation Approach

Methodology / Description

Bottom-Up Epidemiological & Procedure Modeling

Estimating the target patient population from hemorrhagic stroke intracranial aneurysm, cSICH, AVM, and other neurovascular procedures. Incidence, prevalence, treatment rates, and device utilization are used to estimate the market size.

Top-Down Revenue Triangulation

Analyzing neurovascular device market revenues and allocating the hemorrhagic stroke treatment market based on product categories, indication mix, geographic split, pricing trends, and company financials from key players, investors, and industry databases.

Demand-Side Care-Setting & Device Mix Modeling

Modeling procedure volumes across care settings such as hospitals, specialty centers, ASCs, and emergency departments. Estimations are made by treatment type, embolization/coiling, flow diversion, intrasaccular devices, liquid embolics, adjunctive devices, and access devices to estimate device demand and revenue potential.

Supply-Side Capacity & Utilization Modeling

Evaluating global and regional manufacturing capacities, product availability, launch pipelines, physician adoption rates, procedure utilization trends, and pricing dynamics to estimate achievable supply and identify capacity constraints affecting market growth.

Data Triangulation & Market Reconciliation

Synthesizing outputs from multiple models using primary research, hospital and procedure data, company reports, regulatory filings, trade databases, and expert insights to develop a robust and validated market size estimate, with verification of assumptions and sensitivity analysis.

Delivered Customizations

This report has been delivered with the following In-depth customizations

Client Request

Customization Delivered

Value Adds

ASP and volume analysis (historical and forecast)

Comprehensive ASP (Average Selling Price) and volume analysis for the hemorrhagic stroke treatment devices market across 2021-2033, segmented by treatment type, indication, device, and end use. The analysis covers Aneurysm & Hemorrhagic Stroke Interventions by Intracranial Aneurysm, cSDH (MMA Embolization), and AVM & AVF Embolization; devices including Embolization Coiling Systems, Flow Diversion Systems, Intrasaccular Flow Disruption Devices, Liquid Embolization Agents, Adjunctive & Vasospasm Management Devices, and Ancillary & Procedural Access Devices; and end uses including Hospitals, Specialty Neurosurgery Centers, and Ambulatory Surgical Centers.

Enables long-term revenue and volume forecasting, pricing assessment, identification of premium device segments, and evaluation of product mix across aneurysm and hemorrhagic stroke interventions and end-use settings.

Procedure epidemiology and patient population analysis

Detailed assessment of the patient population and procedure volumes associated with Intracranial Aneurysm, cSDH (MMA Embolization), and AVM & AVF Embolization, including utilization patterns for Embolization Coiling Systems, Flow Diversion Systems, Intrasaccular Flow Disruption Devices, Liquid Embolization Agents, Adjunctive & Vasospasm Management Devices, and Ancillary & Procedural Access Devices. Includes procedure-volume estimation, patient segmentation, treatment utilization, and demand patterns across Hospitals, Specialty Neurosurgery Centers, and Ambulatory Surgical Centers.

Supports accurate demand forecasting, treatment-volume estimation, capacity planning, and assessment of device utilization across key hemorrhagic stroke treatment procedures and healthcare settings.

Market share analysis by manufacturer and product type

Revenue- and volume-based market share analysis across the defined Hemorrhagic Stroke Treatment Devices Market segments, covering Embolization Coiling Systems including Bare Platinum Coils and Coated / Bioactive Coils; Flow Diversion Systems including Standard Flow-Diverting Stents and Next-Generation / Surface-Modified Flow Diverters; Intrasaccular Flow Disruption Devices including WEB, Contour Neurovascular System, and Luna Aneurysm Embolization System; Liquid Embolization Agents including Non-Adhesive Liquid Embolics and Adhesive Liquid Embolics; Adjunctive & Vasospasm Management Devices; and Ancillary & Procedural Access Devices. Analysis is further segmented by the specified indications and end uses.

Provides insights into competitive positioning, product-level share, device portfolio strength, technology differentiation, and opportunities across the specified hemorrhagic stroke treatment device segments and end-use settings.

Frequently Asked Questions About This Report

About the Author(s)

Medical Devices Research Team

Healthcare · Medical Devices

This report was authored by the medical devices research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the medical devices segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.

Last Updated:

Speak to Analyst

Trusted market insights - try a free sample

See how our reports are structured and why industry leaders rely on Grand View Research. Get a free sample or ask us to tailor this report to your needs.

logo
GDPR & CCPA Compliant
logo
ISO 9001 Certified
logo
ISO 27001 Certified
logo
ESOMAR Member
Grand View Research is trusted by industry leaders worldwide
client logo
client logo
client logo
client logo
client logo
client logo